Aprea
Doylestown, US · 3 known investors
Aprea Therapeutics is a biopharmaceutical company developing novel cancer therapies targeting DNA damage response pathways to treat solid tumors including ovarian, colorectal, prostate, and breast cancers. The company's lead programs are APR-1051, a WEE1 kinase inhibitor, and ATRN-119, an ATR inhibitor, both in clinical development.
Founders & leadership
JP
John P. HamillinExecutive
OG
Oren GiladChief Executive Officer, President
Board
JB
Jean-Pierre BizzariBoard director
GG
Gabriela GruiaBoard director
RP
Rifat PamukcuBoard director
BS
Bernd SeizingerBoard director
MD
Marc DueyBoard director
JB
John B. HennemanBoard director
MG
Michael GrissingerBoard director
RP
Richard PetersBoard director
Investors · 3
Reported raises · per SEC filings
Form D private placements▶$3.1MraisedDec 2025 · 8 investors · BiotechnologyRule 506(b)
▶$3.1MraisedDec 2025 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John P. HamillExecutive Officer
- Jean-Pierre BizzariDirector
- Gabriela GruiaDirector
- Rifat PamukcuDirector
- Bernd SeizingerDirector
- Marc DueyDirector
- John B. HennemanDirector
- Oren GiladExecutive Officer, Director
- Michael GrissingerDirector
- Richard PetersDirector
- Offering amount
- $5.8M
- Amount sold
- $3.1M
- Sales commissions
- $210K
- Placement agents
- Maxim Group LLC
- First sale
- Dec 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2023 | $862.2K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Aprea do?
- Aprea Therapeutics is a biopharmaceutical company developing novel cancer therapies targeting DNA damage response pathways to treat solid tumors including ovarian, colorectal, prostate, and breast cancers. The company's lead programs are APR-1051, a WEE1 kinase inhibitor, and ATRN-119, an ATR inhibitor, both in clinical development.
- Who are Aprea's investors?
- Aprea's investors include 5AM Ventures, HealthCap, Versant Ventures.
- Where is Aprea headquartered?
- Aprea is headquartered in Doylestown, US.